Topical sirolimus for the treatment of angiofibromas in a child with tuberous sclerosis complex: First reported case in the Philippines

@#<p style="text-align: justify;"><strong>INTRODUCTION:</strong> Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder causing a mutation in the tumor suppressor genes, TSC1 or TSC2. Loss of function of these genes leads to dysfunction of hamartin and tuberin, resulting in hamartoma formation. It usually manifests with cutaneous manifestations at childhood. However, it also affects other organ systems. Based on the Philippine Dermatological Society Health Information System census, there have been 104 cases of TSC from 2011-2018. Currently, limited data is available regarding the treatment options in the local setting.</p><p style="text-align: justify;"><strong>CASE REPORT:</strong> The case involves a 4 year-old boy, with a two year history of flesh-colored to dusky red fi rm papules on the centrofacial areas and neck. Lesions have been increasing in number since first appearance. He had a normal birth history. Family history was insignificant. However, delay in expressive speech development was noted. Physical examination revealed multiple well-defined angiofibromas on centrofacial areas and neck; fibrous cephalic plaque on the left temporal area, and several ash-leaf spots on the trunk. Periungual and subungual fibromas, confetti macules, shagreen patch and dental pits were absent. Based on the clinical manifestations, he was diagnosed with TSC. Histopathology of a papule on the chin was consistent with angiofibroma. Parents were concerned with the appearance of the lesions and preferred conservative management. Hence, topical sirolimus 0.2% ointment was applied once daily on the angiofibromas for 4 months. Monthly follow-up showed marked improvement, manifested by the decrease in number and by flattening of the lesions.</p><p style="text-align: justify;"><strong>CONCLUSION:</strong> To the best of our knowledge, this is the fi rst case report of successful treatment of topical sirolimus for TSC in the Philippines.</p><p style="text-align: justify;"><strong>KEYWORDS:</strong> tuberous sclerosis complex, topical, treatment success, conservative management, hematoma</p>

A comparison of treatment outcomes among HIV positive tuberculosis patients receiving DOTS and fixed dose combination in Visakhapatnam

Background: Tuberculosis is a communicable disease which requires special attention in HIV patients. According to newer guidelines, the treatment regimen for tuberculosis has been changed from intermittent DOTS to daily FDC. This study was taken up to explore effectiveness of fixed dose combination in comparison to intermittent DOTS. Objective was to compare the treatment outcomes for tuberculosis among HIV positive TB patients receiving intermittent DOTS with those receiving daily fixed dose combination (FDC).Methods: A retrospective cohort study was done during November 2017. The data was collected from patient records in an ART centre, attached to King George Hospital, Visakhapatnam. All the HIV patients newly registered for anti-tubercular treatment at the ART center, during 1st quarter of 2016(intermittent DOTS) were compared with those registered during 1st quarter of 2017(FDC). The treatment outcomes include (1) treatment success (completed/ cured), and (2) other treatment outcomes (lost to follow up (LFU), Death). Data was analysed using MS Excel. Association of factors affecting treatment outcomes was tested using chi-square test.Results: Out of a total 83 patients, 34 were on intermittent DOTS and 49 on FDC. The percentage of treatment success in intermittent DOTS was higher than FDC (p=0.06, chi-square value=3.42). The percentage of deaths in FDC is high when compared to intermittent DOTS (P=0.74, chi-square=3.1762). In subject receiving FDC, it was observed that more females had treatment success as compared to males (p=0.28, chi square=1.13).Conclusions: There is no statistically significant difference in the TB treatment outcomes of intermittent DOTS and FDC.

El amparo económico para mejorar el tratamiento de la tuberculosis / Economic protection law for improved tuberculosis treatment

Regulatory Decree 170/91 of Law 10436 created a legal framework designed to ensure the socio-economic protection of patients suffering from TB. It consisted of the monthly payment of a minimum salary for employees in the local public administration. The evaluation criteria employed by the health team assessed who could be included in the protection law, their social situation and permanent residence of at least two years in the province of Buenos Aires, Argentina. The aim of our study was to analyze the differences in clinical and epidemiological data between patients included in the law and those not included, and whether the benefit was a factor in the outcome of the treatment. We describe a retrospective observational study that took place from January 1, 2004 to December 31, 2016. People receiving the benefit showed a good outcome in 93.1% of the total cases, 91.1% in confirmed lung cases, 83.7% in the TB-HIV association / AIDS and 81.5% in MDR-TB. In patients not receiving the benefit the success rates were 74.4%, 73.9%, 53.6% and 58.9%, respectively. The differences were statistically significant between both groups. The economic protection law was essential in motivating the patients and in following those cases of difficult management, thus improving treatment adherence. Overcoming TB means not only improving the use of current tools and interventions but also considering the possibility of extending or approving similar laws in Argentina.

Mediante la aprobación del Decreto Reglamentario 170/91 de la Ley 10436, se crea un régimen de amparo, destinado a asegurar la protección socioeconómica del paciente afectado de tuberculosis (TB). Consiste en el pago mensual de un salario básico de la administración pública provincial. El equipo de salud es el que evalúa quiénes se encuentran en condiciones de ser incluidos en la ley de amparo. Los criterios de evaluación contemplan la situación social y una residencia permanente, como mínimo de dos años en la Provincia de Buenos Aires. El objetivo de nuestro estudio es analizar las diferencias de los datos clínicos y epidemiológicos entre pacientes con y sin inclusión en el régimen de amparo y si el subsidio fue factor de éxito en el tratamiento. Este es un estudio observacional retrospectivo, realizado entre el 1º de enero de 2004 al 31 de diciembre de 2016. Las personas con subsidio mostraron éxito en 93.1% en el total de los casos, 91.1% en los casos pulmonares confirmados, 83.7% en la asociación TB-VIH/SIDA y 81.5% en tuberculosis multirresistente (MDR-TB). Sin subsidio el éxito fue 74.4%, 73.9%, 53.6% y 58.9% respectivamente. Las diferencias fueron estadísticamente significativas entre ambos grupos. El régimen de amparo económico, fue primordial para motivar y retener los casos de difícil manejo, mejorando la adhesión al tratamiento. Poner fin a la TB, consistirá, en mejorar el uso de las herramientas e intervenciones actuales y considerar la posibilidad de extender o aprobar leyes similares en el ámbito de nuestro país.

Effect of comprehensive intervention on the treatment success rate of patients with traumatic shock / 局解手术学杂志

Objective To investigate the effect and medical satisfaction of comprehensive intervention on the treatment success rate of patients with traumatic shock.Methods From February 2012 to February 2015,71 patients with traumatic shock were admitted into our hos-pital,and they were randomly divided into the observation group (36 cases)and the control group (35 cases)according to the random num-ber table method.Routine medical measures were adopted in the control group,while comprehensive intervention measures were taken on the basis of routine medical measures in the observation group.And then compared the treatment success rate,complications and medical satisfac-tion rate of the two groups.Results The treatment success rate was 94.44% in the observation group and 74.29% in the control group,the difference was statistically significant (P <0.05).The rate of complications occurred during the treatment was 16.67% (6 /36)in the obser-vation group,while it was 40% (14 /35)in the control group,and the difference was statistically significant(P <0.05).In the observation group,there was 29 cases (80.56%)of satisfied,6 cases (16.67%)of basically satisfied,and 1 cases (2.78%)of dissatisfied.In the con-trol group,there was 19 cases (54.29%)of satisfied,10 cases (28.57%)of basically satisfied,and 6 cases (17.14%of dissatisfied.The difference of satisfaction rate in the two groups was statistically significant(P <0.05).Conclusion Comprehensive inter-vention can efficiently improve the treatment success rate in patients with traumatic shock,reduce the rate of complications occurred during the treatment,help to improve the prognosis of the patients,and improve the medical satisfaction rate of patients.

Tratamiento directamente observado de la tuberculosis en un hospital de la Ciudad de Buenos Aires / Directly observed treatment for tuberculosis in a Buenos Aires City hospital

Se describe la experiencia en la aplicación del tratamiento directamente observado de tuberculosis (TDO) en el período 1/1/1979-31/12/2009 y la comparación de los resultados obtenidos en el periodo 1979-1999 versus los de 2000- 2009. En un hospital de la Ciudad de Buenos Aires, 582 pacientes HIV negativos recibieron inicialmente rifampicina, isoniazida, pirazinamida y etambutol o estreptomicina. En la segunda fase 424 de estos pacientes tratados entre 01/01/1979 y 31/12/1999 (G1), recibieron esquemas bisemanales con rifampicina/isoniazida o isoniazida/estreptomicina y otros 158 pacientes, tratados entre 01/01/2000 y 31/12/2009 (G2) recibieron un esquema bisemanal o trisemanal con rifampicina/isoniazida. Se siguieron las recomendaciones de los programas de control de la Nación y la Ciudad. Los pacientes bajo TDO tuvieron tasas de tratamiento completo más elevadas (82.8% versus 48.7%), (p < 0.0001) con respecto a otros 483, que siguieron tratamiento autoadministrado (AUTO); la edad promedio fue de 36.3 ± 15.3 años, 63.1% eran varones y 69.4% tenían nacionalidad argentina. Presentaron tratamiento previo el 8.9%, comorbilidades el 6.1% y el 70.6% de las formas pulmonares fueron confirmadas bacteriológicamente. El 9.5% presentó efectos adversos a drogas y el sexo masculino presentó mayor frecuencia de abandonos (p = 0.004). Con respecto al G1, en el G2 hubo menor proporción de pacientes argentinos (48.7% vs. 77.1%), (p ≤ 0.0001), mayor frecuencia de comorbilidades (10.7% vs. 4.4%), (p = 0.005), de formas clínicas pulmonares con confirmación bacteriológica (95% vs. 87%), (p = 0.02) y de efectos adversos a drogas (17% vs. 6.6%), (p ≤ 0.0001). Hallamos tasas de cumplimiento total elevadas en TDO (82.8%), similares a las otras publicaciones.

The outcomes of directly observed therapy of tuberculosis (DOT) between 1/1/1979 and 12/31/2009 were analyzed. Results obtained in the 1979-1999 period were compared with those achieved in the 2000-2009 period. In a Buenos Aires City hospital, 582 HIV negative TB patients received rifampin, isoniazid, pyrazinamide and ethambutol or streptomycin in the initial stage, followed by a second stage where patients were included in two groups: G1 composed by 424 patients (period 1/1/1979-12/31/1999) who received either rifampin and isoniazid or rifampin and streptomicin twice a week, and G2, with 158 patients (period 1/1/2000-12/31/2009) who received either rifampin and isoniazid twice or three times a week. National and Buenos Aires City TB Control Programs recommendations were followed. Patients who underwent DOT had higher completeness rates than those included in self-administered therapy (82.8% vs. 48.7%), (p <0.0001). Mean age: 36.3±15.3 years, males: 63.1% and 69.4% were Argentine citizens. A 8.9% had been previously treated, 6.1% had co-morbidities. A 70.6% of pulmonary cases was bacteriologically confirmed, 82.8% of them completed the treatment, while 11.5% defaulted. Adverse effects to antituberculosis drugs were observed in 9.5% of cases; male patients showed higher rates of non adherence. G2 had a lower proportion of native people (48.7% vs. 77.1%), (p ≤ 0.0001), higher frequency of co-morbidities (10.7% vs. 4.4%), (p = 0.005), of bacteriologically confirmed pulmonary cases (95% vs. 87%), (p = 0.02) and more adverse effects than G1 (17% vs. 6.6%), (p ≤ 0.0001). In coincidence with other experiences, this work shows high treatment success rates in patients treated under DOT strategy.

Outcome of children hospitalized with community-acquired pneumonia treated with aqueous penicillin G

OBJECTIVE: To describe the evolution and outcome of children hospitalized with community-acquired pneumonia receiving penicillin. METHODS: A search was carried out for all hospitalized community-acquired pneumonia cases in a 37-month period. Inclusion criteria comprised age >2 months, intravenous penicillin G use at 200,000 IU/kg/day for >48 h and chest x-ray results. Confounders leading to exclusion included underlying debilitating or chronic pulmonary illnesses, nosocomial pneumonia or transference to another hospital. Pneumonia was confirmed if a pulmonary infiltrate or pleural effusion was described by an independent radiologist blind to the clinical information. Data on admission and evolution were entered on a standardized form. RESULTS: Of 154 studied cases, 123 (80 percent) and 40 (26 percent) had pulmonary infiltrate or pleural effusion, respectively. Penicilli was substituted by other antibiotics in 28 (18 percent) patients, in whom the sole significant decrease was in the frequency of tachypnea from the first to the second day of treatment (86 percent vs. 50 percent, p = 0.008). Among patients treated exclusively with penicillin G, fever (46 percent vs. 26 percent, p = 0.002), tachypnea (74 percent vs. 59 percent, p = 0.003), chest indrawing (29 percent vs. 13 percent, p<0.001) and nasal flaring (10 percent vs. 1.6 percent, p = 0.001) frequencies significantly decreased from admission to the first day of treatment. Patients treated with other antimicrobial agents stayed longer in the hospital than those treated solely with penicillin G (16±6 vs. 8±4 days, p<0.001, mean difference (95 percent confidence interval) 8 (6-10)). None of the studied patients died. CONCLUSION: Penicillin G successfully treated 82 percent (126/154) of the study group and improvement was marked on the first day of treatment.

Risk factors associated with bacteriological cure, new infection, and incidence of clinical mastitis after dry cow therapy with three different antibiotics

Factors affecting bacteriological cure rates (BCR) and new intramammary infections (IMI) during the dry period as well as clinical mastitis (CM) during early lactation were investigated in 414 German Holstein dairy cows receiving dry cow therapy. Cows were treated with either benethamine benzylpenicillin (300,000 IU), penethamate hydriodide (100,000 IU), and framycetin sulphate (100 mg, n = 136), or cefquinome (150 mg, n = 135), or benzathine cloxacillin (1,280 mg, n = 143). Overall BCR, IMI, and CM at parturition were 86.4%, 20.7%, and 4.3%, respectively. The three antibiotic treatments differed only in BCR, with cloxacillin yielding better results than the others. Udder quarters from cows with > 4 lactations had a higher risk of IMI and CM at calving. Chronic changes in udder tissues were linked to a lower BCR and were associated with a higher risk of CM during early lactation. The risk of CM at calving was higher in udder quarters with unspecific or subclinical mastitis before drying off. In conclusion, with antibiotic dry cow therapy, age and health status of the udder appear to be major determinants of IMI and CM during the dry period and early lactation, while BCR was associated with the antibiotic type and udder tissue status.

A Public-Private Collaboration Model for Treatment Intervention to Improve Outcomes in Patients with Tuberculosis in the Private Sector / 결핵및호흡기질환

BACKGROUND: The treatment success rates in patients with tuberculosis are known to be lower in the private sector compared to the public sector. To improve treatment outcomes in the private sector we developed a public-private collaboration model for strengthening health education and case holding activities with public health nursing in the private sector. METHODS: We performed a prospective cohort study in new smear positive pulmonary tuberculosis patients treated at private hospitals, selected by non-randomization, with an intervention consisting of health education and case holding activities by specially trained public health nurses (intervention group) results were compared with cases treated without the intervention (conventional group). Physicians were asked to treat both groups routinely. The treatment outcomes of patients under treatment by the National Tuberculosis Programme were also analyzed for comparison. RESULTS: There were 172 cases each in the intervention and conventional groups. The mean age was 48.9+/-19.0 and 48.2+/-19.7 in the respective groups (p=0.66). The PHN interacted with the cases in the intervention group by initial face to face interview and telephone calls an average of 7.1+/-9.2 times during the initial six months. The intervention group showed a significantly higher treatment success rate, 91.6%, (Rate Ratio [RR]; 1.23, 95% Confidence Interval [CI]; 1.12~1.36), lower default, 3.6%, (RR; 0.31, 95% CI; 0.13~0.75) and transfer-out rate, 3.0%, (RR; 0.32, 95% CI; 0.12~0.86) than the conventional group where they were: 75.0%, 11.6%, 9.3%, respectively. The success rate was even higher than the rate (80.5%) of 1,027 cases treated in health centers (RR; 1.11, 95% CI; 1.05~1.17). Of the completed cases in the intervention group, 82.2% regarded the role of the public health nurse as very helpful. CONCLUSION: The treatment success rate, of tuberculosis patients in the private sector, was significantly improved by an intervention using a public-private collaboration model.